频率、分类和时间的运动障碍快速进行性痴呆(好- 11.004)

文摘
摘要目的:比较和分类运动障碍患者的快速进行性痴呆(RPD)的具体原因。
背景:许多疾病与RPD同在。广义微分为临床医生提供了一个独特的挑战,必须迅速组织和解释测试提供一个及时RPD患者的临床诊断。运动障碍与几个不同的原因RPD;他们的出现、分类和发展可能提供具体RPD患者诊断的线索。
设计/方法:RPD患者前瞻性的2016年2月到2022年8月在两个三级保健中心。两个神经病学家独立确定病原学诊断。第三个神经系统地回顾了研究记录识别运动障碍(如帕金森症、震颤、共济失调、肌阵挛,肌张力障碍,等等)和分类这些当礼物。RPD运动障碍之间的关系和具体的原因被认为是使用确切概率法。
结果:154名患者遇到RPD标准(46.7%的女性)。发病age-at-symptom中位数为66.0岁(范围:18.3 - -84.7年)。运动障碍检测演示在45/154(29.2%)患者和73/154(47.4%)的患者在疾病过程中。步态障碍(n = 40岁,52.6%)是最常见的运动障碍,其次是震颤(n = 30, 40.5%),刚度(n = 24日32.4%),共济失调(n = 19岁,25.7%)和肌阵挛(n = 19岁的25.7%)。运动障碍的人更常与朊病毒疾病(或= 3.65,95% CI 1.27 - -11.93, p = 0.008),和出现在平均89天后症状发作。检测肌阵挛(或= 6.80,95% ci 2.0 - -22.54, p < 0.005)与库贾氏症的几率更高,平均时间从出现症状到肌阵挛的118天。动作迟缓与阿尔茨海默病相关的痴呆(或= 7.38,95% ci 1.54 - -46.14, p = 0.004)。
结论:运动障碍的检测和分类可能通知RPD患者病原学诊断。
披露:Turcano博士没有披露。Satyadev先生没有披露。已收到博士蒂普顿个人薪酬在500 - 4999美元的范围为AbbVie担任顾问。已收到博士蒂普顿个人薪酬在500 - 4999美元的范围作为演讲者田纳西州与阿尔茨海默氏症。已收到博士蒂普顿个人薪酬在500 - 4999美元的范围与夏洛特县医疗社会作为一个演讲者,Inc .博士一天已收到个人薪酬在5000 - 9999美元的范围为Parabon Nanolabs担任顾问。天已收到博士个人薪酬制度在5000 - 9999美元的范围为礼来公司担任顾问。天已收到博士个人薪酬在500 - 4999美元的范围作为一个编辑,副主编,或编辑顾问委员会成员力学(EBSCO健康)。天已收到博士个人薪酬在10000 - 49999美元的范围为巴罗法作为专家证人。天博士ANI制药公司的股票。天已收到博士研究机构国立卫生研究院/ NIA的支持。 The institution of Dr. Day has received research support from Chan Zuckerberg Initiative. The institution of Dr. Day has received research support from Alzheimer’s Association. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Horizon Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with American Academy of Neurology. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing Education, Inc. Dr. Day has a non-compensated relationship as a Clinical Director with AntiNMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.